Alumis (NASDAQ:ALMS) Reaches New 12-Month High – Should You Buy?

Alumis Inc. (NASDAQ:ALMS)’s stock price hit a new 52-week high on Tuesday . The company traded as high as $22.30 and last traded at $18.8590, with a volume of 30153270 shares changing hands. The stock had previously closed at $8.31.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Phase‑3 success for envudeucitinib drove the rally — two plaque psoriasis trials met all endpoints with strong skin‑clearance and favorable safety, prompting large intraday gains and record highs as the market re‑rates the drug’s commercial potential and a planned 2026 FDA filing. Read More.
• Positive Sentiment: Analysts responded with upgrades and higher targets — multiple firms raised price targets (Guggenheim to $32; Morgan Stanley, Wells Fargo and others published bullish notes), increasing upside expectations and reinforcing demand. Read More.
• Neutral Sentiment: Valuation commentary surfaced after the data — coverage assessing ALMS valuation emphasizes strong momentum but warns investors to weigh upside against remaining clinical/regulatory and commercial execution risk. Read More.
• Negative Sentiment: Company priced an upsized public offering of 17.65M shares at $17.00 (≈$300M gross) to fund its immune‑disease pipeline; while proceeds boost the balance sheet and program funding, the new‑share issuance dilutes existing holders and likely capped a portion of the post‑trial rally. Read More.
• Negative Sentiment: The market reaction reflects a mix of enthusiasm and profit‑taking — large underwritten deals and aftermarket selling can pressure the price even when fundamentals improve, creating short‑term volatility. Read More.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Oppenheimer reissued an “outperform” rating and set a $50.00 price target on shares of Alumis in a report on Tuesday. Guggenheim boosted their target price on shares of Alumis from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group restated an “outperform” rating on shares of Alumis in a research note on Tuesday. Wall Street Zen raised Alumis from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, Citigroup reiterated an “outperform” rating on shares of Alumis in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $34.33.

Alumis Trading Down 0.7%

The stock has a market cap of $1.86 billion, a price-to-earnings ratio of -4.39 and a beta of -2.09. The company has a fifty day simple moving average of $8.65 and a 200-day simple moving average of $5.71.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. As a group, analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.

Insider Buying and Selling at Alumis

In other Alumis news, Director James B. Tananbaum bought 190,500 shares of the firm’s stock in a transaction on Wednesday, November 19th. The stock was bought at an average cost of $6.56 per share, with a total value of $1,249,680.00. Following the completion of the transaction, the director directly owned 2,542,003 shares of the company’s stock, valued at approximately $16,675,539.68. The trade was a 8.10% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Foresite Capital Management Vi purchased 190,500 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average price of $6.56 per share, for a total transaction of $1,249,680.00. Following the acquisition, the insider directly owned 2,542,003 shares in the company, valued at $16,675,539.68. This represents a 8.10% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 2,788,875 shares of company stock worth $18,352,357 over the last ninety days. 40.70% of the stock is currently owned by insiders.

Institutional Trading of Alumis

Several large investors have recently modified their holdings of the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Alumis during the third quarter worth approximately $160,000. Woodline Partners LP grew its holdings in shares of Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after purchasing an additional 1,558,660 shares during the last quarter. PharVision Advisers LLC bought a new position in shares of Alumis in the third quarter valued at approximately $83,000. Prelude Capital Management LLC increased its stake in shares of Alumis by 698.0% in the third quarter. Prelude Capital Management LLC now owns 87,832 shares of the company’s stock valued at $350,000 after buying an additional 76,825 shares in the last quarter. Finally, Mariner LLC lifted its holdings in Alumis by 177.3% during the 3rd quarter. Mariner LLC now owns 84,873 shares of the company’s stock worth $339,000 after buying an additional 54,269 shares in the last quarter.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.